Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.

ABSTRACT:

Importance

Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited.

Objective

To evaluate the immunogenicity of COVID-19 messenger RNA (mRNA) vaccines in pregnant and lactating women, including against emerging SARS-CoV-2 variants of concern.

Design, setting, and participants

An exploratory, descriptive, prospective cohort study enrolled 103 women who received a COVID-19 vaccine from December 2020 through March 2021 and 28 women who had confirmed SARS-CoV-2 infection from April 2020 through March 2021 (the last follow-up date was March 26, 2021). This study enrolled 30 pregnant, 16 lactating, and 57

SUBMITTER: Collier AY 

PROVIDER: S-EPMC8120446 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature